ArticleFrontiers in pharmacology2025

Cost-effectiveness analysis of CDK4/6 inhibitors in the second-line treatment for HR+/HER2- advanced or metastatic breast cancer.

Kaixuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.